Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06433752
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2024-05-23
Brief Title:
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI Ublituximab-xiiy for Relapsing Multiple Sclerosis RMS
Sponsor:
TG Therapeutics Inc
Organization:
TG Therapeutics Inc
Study Overview
Official Title:
REal World ExperieNce With BRIUMVI UblituximAB-xiiy Treated Patients A Longitudinal REgistry Study ENABLE
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ENABLE
Brief Summary:
The purpose of this study is to evaluate safety effiectiveness and to gain insight into the treatment experience of participants prescribed BRIUMVI ublituximab-xiiy in the real-world setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None